Article
Transcriptional Activation of p21waf1/cip1 by Alkylphospholipids
15 Jan 2004
Abstract excerpt
Alkylphospholipids (ALKs) are a novel class of antitumor agents with an unknown mechanism of action. The first ALK tested in the clinic, miltefosine, has been approved recently in Europe for the local treatment of patients with cutaneous metastasis. Perifosine, the only available oral ALK, is being studied currently in human cancer clinical trials. We have shown previously that perifosine induces p21(waf1/cip1)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
